IO Biotech to Reduce Headcount by 50% Amid Restructuring

Dow Jones

09/29

By Connor Hart

IO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies.

The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance.

Shares tumbled 75% to 39 cents in premarket trading.

IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added.

The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring.

IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 29, 2025 07:46 ET (11:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571059380"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571059380\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571059380?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-29 19:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571059380","market":"other","top_or_hot":-1,"title":"IO Biotech to Reduce Headcount by 50% Amid Restructuring","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n</p>\n<p>\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n</p>\n<p>\n  Shares tumbled 75% to 39 cents in premarket trading. \n</p>\n<p>\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n</p>\n<p>\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n</p>\n<p>\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 07:46 ET (11:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IO Biotech to Reduce Headcount by 50% Amid Restructuring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIO Biotech to Reduce Headcount by 50% Amid Restructuring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-29 19:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/IOBT\">IO Biotech</a> will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n</p>\n<p>\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n</p>\n<p>\n  Shares tumbled 75% to 39 cents in premarket trading. \n</p>\n<p>\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n</p>\n<p>\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n</p>\n<p>\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 29, 2025 07:46 ET (11:46 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOBT","symbol_name":"IO Biotech, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2571059380","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571059380","pubTimestamp":1759146360,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"IO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies.The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance.Shares tumbled 75% to 39 cents in premarket trading.IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added.The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the res","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOBT":"IO Biotech, Inc.","BK4139":"生物科技"},"translate_title":"IO Biotech将在重组中裁员50%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOBT":1.5},"content_text":"By Connor Hart \n\n\n \n\n\nIO Biotech will lay off approximately half of its employees, or around 40 workers, in a restructuring aimed at conserving capital while the company works to complete current studies. \n\n\n  The restructuring comes after the biopharmaceutical company said on Monday that the Food and Drug Administration recommended it not to submit a biologics license application for its cancer vaccine, Cylembio. The recommendation followed results from a recent trial that the company said narrowly missed statistical significance. \n\n\n  Shares tumbled 75% to 39 cents in premarket trading. \n\n\n  IO Biotech said it will continue pursuing a pathway to regulatory approval for Cylembio while working to complete current studies. The company currently has capital to run its operations into next year's first quarter, it added. \n\n\n  The company said it expects its restructuring to reduce its continuing expense structure and anticipates a non-recurring charge of between $1 million and $1.5 million in the current quarter stemming from the restructuring. \n\n\n  IO Biotech had 80 full-time employees at the end of 2024, according to the most recent headcount available in Securities and Exchange Commission filings. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 29, 2025 07:46 ET (11:46 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}